Deals In Depth: November 2016
Executive Summary
In the largest single-territory deal (worth $434 million) by a South Korean pharmaco, Kolon Life Science licensed Mitsubishi Tanabe Japanese rights to an osteoarthritis gene therapy; Allergan continued its dealmaking spree, paying up to $1 billion for Alzheimer's company Chase. Biopharma financing rebounded thanks to Samsung BioLogics' record-breaking IPO.